BI 3034701 dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
BI 3034701 is Boehringer Ingelheim's drug that works on three signals: GLP-1, GIP and NPY2, a fullness signal from the gut. It started a mid-stage study in July 2026. There are no results in people yet.
Evidence grade for BI 3034701: Preliminary. The rule: studied in people, but no published study has had people take it. The sum on this page: 2 human studies where nobody was given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 0
- Human studies
- 0
- Found nothing
- 0
Dose
No human dose established
No published study on this page has given this compound to people and reported a result.
2 human studies where nobody was given it
1 effects reported, 1 unwanted, by people using it, not a trial
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
BI 3034701 is an experimental shot from Boehringer Ingelheim. It works on three signals, GLP-1, GIP and NPY2. NPY2 carries the fullness signal your gut sends after a meal. It is not approved.
What people take it for
- Weight loss with more fullness.
- A new kind of three-signal drug.
What studies in people showed
There are no results in people yet. Early safety testing went well, the company says. A mid-stage study to find the right dose started in July 2026. In animals, adding an NPY2 drug to survodutide took off more weight than survodutide alone.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- No results or side effect data in people have been published yet.
Where these come from: Everything here is from the study record, the company release and the animal study on this page. There are no user reports.
My bottom line
First of its kind is news, not evidence. Nothing to buy and nothing to do.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Animal and lab work, not yet tested in people
Real results, but from animals or cells, not people. What works in a mouse often does not work the same way in a person. Nobody can patent this, so nobody would ever earn back the cost of a study in people. That is usually why there is none.
- Losing weight1 animal or lab study
35 of the 36 indexed goals have no study of any kind behind BI 3034701
No study in people, animals or cells on this page reports a result for these. That does not prove BI 3034701 does nothing for them. It does mean anything you have heard about BI 3034701 and one of these did not come from a study cited here.
Show full evidence
What is BI 3034701?
BI 3034701 is Boehringer Ingelheim's drug that works on three signals: GLP-1, GIP and NPY2, a fullness signal from the gut. It started a mid-stage study in July 2026. There are no results in people yet.
Most three-signal drugs work on GLP-1, GIP and glucagon. BI 3034701 swaps glucagon for NPY2. That receptor carries the fullness signal of PYY, a gut hormone released after meals. It is a way to add fullness without adding glucagon. Boehringer Ingelheim said early safety testing in people went well, and it started a mid-stage dose-finding study in July 2026. That makes it the first drug of this kind to reach that stage in people. No results on weight loss in people have been reported. In animals, the NPY2 approach added to the weight loss from survodutide, a GLP-1 and glucagon drug.
How does BI 3034701 work?
It turns on the GLP-1, GIP and NPY2 signals. The NPY2 part copies PYY, a gut hormone that turns down appetite after a meal.
The evidence, in charts
Fig. 1a · how many people
2studies in people cited, but none says how many people took part
number of people not stated
We do not draw a total, because none of the studies in people on this page gives one. Read the sources below for what each study measured.
We read the number of people from the source lines on this page. Where a line gives no number, we count nothing for it. We do not guess.
Fig. 1b · evidence mix
2 of 3 sources here are studies in people. The rest is not.
- Study in people · done in people267%
- Animal study · done in animals133%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
Sources here come from just two years, 2025 and 2026.
Too few different years on this page to draw a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- Not disclosed
- Half-life
- Stated in words, not a numbersee the exact wording below
- Chain length
- None on file
No amino acid sequence is on file for BI 3034701, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2026BI 3034701 Phase 2 dose-finding in obesity
This trial started in July 2026 and has published nothing. It is a dose-finding study, which means it is looking for the amount that works rather than proving the drug works at all. No weight loss figures have been reported for this drug in people, at any dose. Everything said about it so far rests on animal work.
Dose-finding trial started July 2026.
- Study in people2026Boehringer Ingelheim strengthens obesity pipeline as BI 3034701 enters Phase II
Nobody has published human results for this drug. Boehringer Ingelheim announced that it is the first of its kind to reach trials in people. It hits three targets at once and swaps the usual third target for the one that carries the natural fullness signal after a meal. Being first is a fact about the field, not evidence about the drug. Early safety testing went well, and that is all that has been said.
First clinical-stage NPY2-containing triple agonist.
- Animal study2025NPY2 receptor agonism synergizes with a GLP-1/glucagon dual agonist in preclinical models
In animals: adding an NPY2 drug to survodutide took off more weight than survodutide alone.
Additive weight loss with survodutide in animals.
Where to buy BI 3034701
No seller we track lists BI 3034701 yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has BI 3034701 been tested in people?
Not in a completed trial cited here. 2 human studies where nobody was given it. BI 3034701 is Boehringer Ingelheim's drug that works on three signals: GLP-1, GIP and NPY2, a fullness signal from the gut. It started a mid-stage study in July 2026. There are no results in people yet.
What is the BI 3034701 dosage?
No human dose established. No published study on this page has given this compound to people and reported a result. 2 human studies where nobody was given it
Is BI 3034701 FDA-approved?
Investigational; in mid-stage studies
What is NPY2?
It is a receptor for peptide YY, a gut hormone released after meals that tells you that you are full. Hitting it is a way to add fullness without adding glucagon.